3 Small-Cap Biotech Stocks to Buy for Major Upside

The biotech industry is currently experiencing a period of robust growth and expansion, driven by increasing investments, strong demand, and a revitalized IPO market. Recent announcements from the Federal Reserve regarding interest rate cuts signal a more favorable environment for market operations, which augurs well for investors looking to capitalize on solid small-cap biotech stocks. Specifically, BioCryst Pharmaceuticals, Inc. (BCRX), Harmony Biosciences Holdings, Inc. (HRMY), and Entrada Therapeutics, Inc. (TRDA) present significant upside potential for those willing to invest in the innovative biotech landscape.

Market Dynamics and Trends

The biotech industry showed significant resilience in 2024, boosted by pent-up demand and advances in research technologies, alongside an optimistic outlook for IPOs. September notably marked the busiest month for healthcare IPOs, driven by strong initial market performances. Furthermore, recent discoveries in critical areas like oncology, immunology, and neurology are being actively supported by growing investments. According to Biopharma Dive, more than 12 mergers and acquisitions (M&A) agreements were reported during the second quarter, showcasing a strong wave of biotech activity.

The Federal Reserve’s recent decision to implement its first interest rate cut in over four years is expected to ease the funding environment for biotech organizations, particularly smaller firms that are often in need of capital to fuel their R&D. Enhanced R&D initiatives coupled with a global digital technology adoption trend further underscore the growth potential within this sector. According to a report by Precedence Research, the global biotechnology market is projected to reach $4.61 trillion by 2034, growing at a compound annual growth rate (CAGR) of 11.5%. This macroeconomic backdrop makes small-cap biotech stocks particularly attractive, as they typically offer a lower entry point and substantial growth opportunities.

Top Small-Cap Biotech Stocks

BioCryst Pharmaceuticals, Inc. (BCRX)

BioCryst Pharmaceuticals specializes in the development of oral small-molecule and protein therapeutics aimed at treating rare diseases. The company is recognized for its marketed products including RAPIVAB, an intravenous neuraminidase inhibitor for acute influenza management, and ORLADEYO, an oral protease inhibitor for hereditary angioedema.

Significantly, on September 30, BCRX was awarded a $69 million contract by the U.S. Department of Health and Human Services for the procurement of up to 95,625 doses of RAPIVAB over the next five years. Additionally, in July, approval was given for ORLADEYO in Peru to treat hereditary angioedema in pediatric patients.

For the second quarter ending June 30, 2024, BCRX reported a 32.5% increase in total revenues, marking $109.33 million. Analysts anticipate a continued upward trajectory with expected third-quarter revenues projected at $113.89 million, reflecting a growth of 31.3% year-over-year. As of the latest data, BCRX shares have surged by 56.2% over the past six months, with analysts predicting a target price of $15.33, offering a remarkable upside of 116.07%. Overall, BCRX holds strong ratings across various performance metrics and is ranked 21st out of 331 stocks in the Biotech sector.

Harmony Biosciences Holdings, Inc. (HRMY)

Harmony Biosciences is focused on commercializing therapies for rare and neurological diseases, prominently featuring its drug WAKIX, intended for treating excessive daytime sleepiness in narcolepsy patients. The groundbreaking approval of WAKIX for pediatric patients marks a significant milestone for the company.

During the second quarter of 2024, HRMY reported net product revenue growth of 28.8%, reaching $172.81 million, alongside a gross profit increase of 28.8%. Analysts expect HRMY’s revenue to grow to $184.81 million in the forthcoming quarter with an EPS of $0.68, indicating steady growth. Currently priced at $34.75, analysts forecast a target price of $52, suggesting a potential upside of nearly 49.38%. HRMY also holds a strong positioning within the biotech rankings, placing 14th.

Entrada Therapeutics, Inc. (TRDA)

Entrada Therapeutics operates in the clinical-stage biotechnology space, developing endosomal escape vehicle therapeutics for neuromuscular diseases. Its promising Phase 1 trial results for ENTR-601-44 showcased significant improvements, paving the way for future developments and patient trials.

TRDA exhibited astounding revenue growth, with a 421.1% year-over-year increase in collaboration revenue during the second quarter, amounting to $94.69 million. Net income reached $55.03 million, a resurgence from a loss in the previous year, revealing the company’s financial soundness. Analysts project TRDA’s revenue to climb to $175.89 million in 2024, with a target stock price of $21.50, representing a robust upside potential of 32.55%. TRDA is well-positioned within its sector, ranking 13th among 331 stocks.

Conclusion

In light of the significant trends and evolving dynamics within the biotech industry, small-cap stocks such as BCRX, HRMY, and TRDA offer appealing avenues for investment. Investors should consider these companies not only for their growth potential but also for their innovative contributions to the healthcare sector, which positions them favorably amid an ever-changing economic landscape.